PANCREATIC CANCER MARKERS

• US 20110236993A1
• Filed: 09/09/2009
• Published: 09/29/2011
• Est. Priority Date: 09/10/2008
• Status: Abandoned Application

• Current Assignee: Board of Regents of the University of Michigan (University of Michigan)
• Original Assignee: Board of Regents of the University of Michigan (University of Michigan)
• Inventors: Li, Chen, Lubman, David M., Simeone, Diane M.
• Application Number:
  US13/060,802
• Publication Number:
  US 20110236993A1
• Time in Patent Office: Days
• US Class Current: 436/501
• CPC Class Codes: G01N 2333/4728 alpha-Glycoproteins
• CPC Class Codes: G01N 33/57438 of liver, pancreas or kidney

Abstract

The present invention relates to pancreatic cancer markers. In particular, the present invention provides methods and compositions for the identification of protein glycosylation patterns associated with pancreatic cancer.

Claims

1. A method of diagnosing pancreatic cancer in a subject, comprising detecting the presence of a cancer marker selected from the group consisting of Alpha-1-β

glycoprotein and amyloid.

2. The method of claim 1, wherein said detecting comprises detecting the presence of a glycosylated cancer marker.

3. The method of claim 2, wherein said detecting comprises the step of binding said cancer marker to a cancer marker specific antibody.

4. The method of claim 3, further comprising the step of contacting said cancer marker with a lectin.

5. The method of claim 3, wherein said lectin is selected from the group consisting of Aleuria aurentia lectin (AAL), Sambucus nigra bark lectin (SNA), and Lens culinaris agglutinin (LCA).

6. The method of claim 5, wherein said lectin is labeled.

7. The method of claim 6, wherein said label is biotin.

8. The method of claim 2, wherein the presence of said glycosylated cancer marker is indicative of pancreatic cancer in said subject.